Gold prices edge higher with focus on Ukraine-Russia, Jackson Hole
SAN DIEGO - Modular Medical, Inc. (NASDAQ:MODD), a developer of insulin delivery systems, announced today the initiation of its manufacturing transfer to Phillips Medisize facilities in Mexico. As the company progresses toward high-volume production, this move marks a significant step in its journey from pre-commercial stages to becoming a major player in the medical device market.
The transfer of pilot line manufacturing operations to Queretaro, Mexico, is occurring alongside the FDA's ongoing 510(k) review process for Modular Medical's MODD1 Insulin Delivery System. Kevin Schmid, the Chief Operating Officer, stated that they expect the manufacturing operation to be validated and ready for production intended for human use early next year.
Phillips Medisize, a subsidiary of Molex, has provided crucial support in developing Modular Medical's supply chain and manufacturing capabilities. The collaboration has extended to various services, including injection molding, packaging, and electronics design and manufacturing. The MODD1 system's assembly will take place in a clean room in Queretaro, while the printed circuit board assembly will be handled in Guadalajara.
Modular Medical aims to simplify and reduce the cost of insulin delivery technology while maintaining clinical efficacy. The company was founded by Paul DiPerna, who previously founded Tandem Diabetes and designed the t:slim insulin pump.
InvestingPro Insights
As Modular Medical, Inc. (NASDAQ:MODD) advances its manufacturing capabilities with a strategic move to Phillips Medisize facilities in Mexico, the company's financial health and market performance provide essential context to investors monitoring its progress. According to InvestingPro data, Modular Medical holds a market capitalization of approximately $48.15 million, indicating a relatively small player in the medical device industry with potential for growth.
An important consideration for investors is the company's financial efficiency and stability. InvestingPro Tips highlight that Modular Medical has more cash than debt on its balance sheet, which is a positive sign for the company's liquidity and financial resilience. Moreover, the company's liquid assets exceed its short-term obligations, suggesting that Modular Medical is well-positioned to manage its current liabilities and invest in its growth initiatives.
However, the company faces challenges, as reflected in the significant negative return on assets of -165.97% over the last twelve months as of Q4 2024. This metric indicates difficulties in generating profit from its assets. Additionally, InvestingPro Tips caution that analysts do not expect Modular Medical to be profitable this year, which could impact investor confidence and the company's ability to attract further investment.
Nevertheless, Modular Medical has shown a strong return over the last year with a 64.08% price total return, underscoring a potential upside for investors who are willing to take on the associated risks. For those interested in deeper analysis, InvestingPro offers a wealth of additional tips, including 9 more tips related to Modular Medical, available at https://www.investing.com/pro/MODD.
With the next earnings date scheduled for August 28, 2024, stakeholders will be keen to assess the company's performance and the impact of its manufacturing transition on its financial outcomes. The fair value estimates from analysts and InvestingPro differ significantly, with analysts targeting a fair value of $5 USD, while InvestingPro's fair value assessment stands at $1.76 USD, which could signal divergent views on the company's valuation and future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.